DRTG(600329)2022-10-30 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥1,788,247,682.39, representing a year-on-year increase of 4.47%[4] - The net profit attributable to shareholders for the same period was ¥260,175,685.17, reflecting a significant increase of 30.77% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was ¥184,375,376.29, which showed a decrease of 3.73% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥0.34, up by 30.77% from the same period last year[5] - The total profit for Q3 2022 was approximately ¥847.92 million, an increase from ¥763.91 million in Q3 2021, representing a growth of about 11.1%[21] - The net profit for Q3 2022 reached approximately ¥746.21 million, compared to ¥677.00 million in Q3 2021, indicating a year-over-year increase of around 10.2%[21] - The net profit attributable to shareholders of the parent company was approximately ¥728.96 million, up from ¥661.51 million in the same quarter last year, reflecting a growth of about 10.1%[22] - The basic earnings per share for Q3 2022 was ¥0.95, compared to ¥0.86 in Q3 2021, marking an increase of approximately 10.5%[22] Assets and Liabilities - The total assets at the end of the reporting period reached ¥9,749,983,806.96, an increase of 7.53% compared to the end of the previous year[5] - The total current assets amounted to 6,915,032,966.25 yuan, an increase from 6,424,993,578.77 yuan at the end of 2021[16] - Non-current assets totaled ¥2,834,950,840.71, an increase from ¥2,642,091,427.30 in the previous year[18] - Current liabilities increased to ¥2,680,520,189.59 from ¥2,433,902,114.44, indicating a rise of 10.14%[18] - The company holds 698,495,037.33 yuan in long-term equity investments as of September 30, 2022[16] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥126,473,611.63, which decreased by 81.32% compared to the previous year[5] - The net cash flow from operating activities for Q3 2022 was approximately ¥126.47 million, a significant decrease from ¥677.11 million in Q3 2021[25] - Cash inflow from investment activities in Q3 2022 totaled approximately ¥653.66 million, compared to ¥189.56 million in Q3 2021, showing a substantial increase[25] - The net cash flow from investment activities for Q3 2022 was approximately ¥155.48 million, a recovery from a net outflow of ¥273.60 million in Q3 2021[25] - The company reported a total operating cash outflow of approximately ¥5.36 billion in Q3 2022, compared to ¥4.84 billion in Q3 2021, reflecting an increase of about 10.5%[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,884[12] - Tianjin Pharmaceutical Group Co., Ltd. is the largest shareholder, holding 331,120,528 shares, accounting for 42.811% of the total shares[12] - The number of shares held by the top ten shareholders includes significant foreign and domestic entities, indicating a diverse shareholder base[12] - The company has not disclosed any related party relationships among the top ten shareholders[13] Strategic Initiatives - The company has seen a 132.07% increase in capitalized research and development expenses, indicating a focus on innovation and new product development[10] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[10] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the provided content[20] Revenue and Costs - Total revenue for the first three quarters of 2022 reached ¥5,563,011,492.12, an increase of 3.94% compared to ¥5,352,222,520.14 in the same period of 2021[19] - Total operating costs for the third quarter amounted to ¥4,908,870,636.98, up from ¥4,743,067,407.38 year-over-year[20] - Operating profit for the third quarter was ¥850,221,307.98, compared to ¥756,079,156.11 in the previous year, reflecting a growth of 12.43%[20] - Research and development expenses for the first three quarters were ¥92,259,923.53, slightly down from ¥94,465,763.49 in the previous year[20] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 54.69%, primarily due to an increase in receivables from sales[10] - Accounts receivable increased to 2,377,623,755.60 yuan from 1,536,992,972.81 yuan year-over-year[16] - Inventory decreased to 1,343,866,721.60 yuan from 1,525,088,939.42 yuan year-over-year[16]